The PARP enzyme and scaffolding protein tankyrase (TNKS, TNKS2) uses its ankyrin repeat clusters (ARCs) to bind a wide range of proteins and thereby controls diverse cellular functions. A number of these are implicated in cancer-relevant processes, including Wnt/bcatenin signaling and telomere maintenance. The ARCs recognise a conserved tankyrasebinding peptide motif (TBM). All currently available tankyrase inhibitors target the catalytic domain and inhibit tankyrase's poly(ADP-ribosyl)ation function. However, there is emerging evidence that catalysis-independent "scaffolding" mechanisms contribute to tankyrase function. Here we report a fragment-based screening program against tankyrase ARC domains, using a combination of biophysical assays, including differential scanning fluorimetry (DSF) and nuclear magnetic resonance (NMR). We identify fragment molecules that will serve as starting points for the development of tankyrase substrate binding antagonists. Such compounds will enable probing the scaffolding functions of tankyrase, and may, in the future, provide potential alternative therapeutic approaches to inhibiting tankyrase activity in cancer and other conditions. 2
Introduction
Tankyrase enzymes (TNKS/ARTD5 and TNKS2/ARTD6; simply referred to as 'tankyrase' from here on; Figure 1A ) are poly(ADP-ribose)polymerases (PARPs) in the Diphtheria-toxinlike ADP-ribosyltransferase (ARTD) family 1, 2 . PARPs catalyse the processive addition of poly(ADP-ribose) (PAR) onto substrate proteins, which can either directly regulate acceptor protein function or serve as docking sites for PAR-binding proteins that mediate downstream signaling 3 . Given the diversity of tankyrase binders and substrates, tankyrase impinges on a wide range of cellular functions 2, [4] [5] [6] . These include Wnt/b-catenin signaling [7] [8] [9] [10] , telomerase-dependent telomere lengthening 11, 12 , sister telomere resolution during mitosis 13, 14 , the control of glucose homeostasis [15] [16] [17] , mitotic spindle assembly 18, 19 , DNA repair 20, 21 , and the regulation of the tumor-suppressive Hippo signaling pathway [22] [23] [24] . Silencing of tankyrase elicits synthetic lethality in BRCA1/2-deficient cancer cells 25 . Given these links of tankyrase to disease-relevant processes, tankyrase has gained attention as a potential therapeutic target 2, 26 .
Many mechanistic aspects of tankyrase function have been revealed by studying its role in
Wnt/b-catenin signaling 10 . Tankyrase . AXIN PARylation either induces its PAR-dependent ubiquitination and degradation 7, [28] [29] [30] , or promotes the Wnt-induced transformation of the destruction complex into a signalosome complex incapable of initiating b-catenin degradation 8, 31 . Tankyrase thus sensitises cells to incoming Wnt signals 32, 33 . The Wnt/b-catenin pathway is dysregulated in the vast majority of colorectal cancers 34 . Inhibiting tankyrase has been explored as a strategy to re-tune oncogenically dysregulated Wnt/b-catenin signaling in cancers with mutations in the tumor suppressor and destruction complex component APC (adenomatous polyposis coli) 10, [35] [36] [37] [38] [39] [40] . Whilst tankyrase inhibitors can suppress tumor cell growth, in-vivo studies have also pointed to different degrees of tankyrase-inhibitor-induced intestinal toxicity in mice 35, 39, 41 . The precise molecular mechanisms by which tankyrase controls Wnt/b-catenin signaling, how tankyrase inhibition can restore oncogenically dysregulated signaling, and the basis of tankyrase inhibitor toxicity are incompletely charted. This warrants the development of different chemical probes to modulate tankyrase function.
To date, drug discovery efforts on tankyrase have focused on inhibiting the catalytic PARP domain 2, 10, 42, 43 . Catalytic inhibition of tankyrase has complex consequences. As well as inhibiting substrate PARylation, catalytic inhibitors prevent tankyrase auto-PARylation and therefore subsequent PAR-dependent ubiquitination and degradation of tankyrase itself 7 .
Consequently, tankyrase inhibition typically leads not only to the accumulation of many of its substrates but also of tankyrase itself 6, 7, 35, 37, 40 . Moreover, catalysis-independent functions of tankyrase are emerging, and these may be accentuated when tankyrase and its substrates accumulate upon tankyrase catalytic inhibition. Surprisingly, we observed that tankyrase can promote Wnt/b-catenin signaling independently of its catalytic PARP activity, at least when tankyrase levels are high 9 . Under these conditions, tankyrase catalytic inhibitors only incompletely block tankyrase-driven b-catenin-dependent transcription, pointing to both catalytic and non-catalytic (scaffolding) functions of tankyrase. Tankyrase scaffolding functions depend on tankyrase's substrate-binding ankyrin repeat clusters (ARCs) and the polymerization function of its sterile alpha motif (SAM) domain (see Figure   1A ) 9 . Tankyrase auto-PARylation has been proposed to limit tankyrase polymerization 44 ; tankyrase catalytic inhibition may therefore induce its hyperpolymerisation, which may further promote scaffolding functions. Scaffolding functions of tankyrase likely extend beyond Wnt/b-catenin signalling: not all tankyrase binders are also PARylated, and noncatalytic roles of tankyrase in other processes have been proposed 4, 5, 45, 46 .
Unraveling the complexity of tankyrase's catalytic vs. non-catalytic functions will require novel tool compounds that block tankyrase-dependent scaffolding. Here, we identify and characterize small molecule fragments that bind to the tankyrase ARC domains, as a first step towards the discovery of compounds capable of blocking the interaction of tankyrase binders and substrates with the ARC domains of tankyrase.
Tankyrase contains five N-terminal ankyrin repeat clusters (ARCs), four of which, namely ARCs 1, 2, 4 and 5, can recruit binders and substrates 4, 47, 48 ( Figure 1A ). ARCs bind conserved but degenerate six-to eight-amino-acid peptide motifs, termed the tankyrase- 4, 49 .
binding motif (TBM, consensus R-X-X-[small hydrophobic or G]-[D/E/I/P]-G-[no P]-[D/E])
Depending on the binding partner, ARCs can be functionally redundant, at least at the level of substrate recruitment 4 , or collaborate in a combinatorial fashion, engaging preferred sets of ARCs in recruiting multivalent tankyrase binders such as AXIN 48 . The TBM-binding pocket contains several binding hotspots ( Figure 1B ). An "arginine cradle" forms the binding site for the TBM's essential arginine residue at position 1; the "central patch" provides an infrastructure for diverse interactions, including hydrophobic contacts with a small hydrophobic residue at TBM position 4 and contact sites for the residue at TBM position 5;
and the "aromatic glycine sandwich", where an essential glycine at TBM position 6 is sandwiched between two aromatic residues 4 .
Mutation of the TBM binding sites in the ARCs abrogates tankyrase's ability to drive Wnt/bcatenin signaling 9 . As a further proof of concept for the feasibility of targeting tankyrase via the ARCs, a sequence-optimized 4 , cell-permeating stapled TBM peptide can compete with AXIN for tankyrase binding and suppress the Wnt-induced expression of a b-cateninresponsive reporter gene in HEK293 cells 50 . Given the uniqueness of ARCs within the PARP family and their strong degree of conservation across both TNKS and TNKS2, interfering with substrate binding would provide high target specificity and inhibition of both TNKS and TNKS2, many of whose functions are redundant 6, 51 .
Herein, we report the identification and characterization of fragments that bind to tankyrase
ARCs at the same site as the TBM peptides. The identified fragments provide a starting point for the development of potent, cell-active tankyrase substrate binding antagonists.
Results

Essentiality of the TBM arginine residue
We first considered a peptidomimetic approach to develop TBM peptides into more potent, stable and drug-like competitors of the ARC:TBM interaction. Given the anticipated impairment of cell permeability by the N-terminal TBM arginine, we investigated whether the guanidine group could be substituted. To prioritise synthesis efforts, we followed an in-silico docking approach 52 , exploring the importance of the positive charge and hydrogen bonding interactions, linker lengths/flexibility and side chain geometry (see Supplementary Materials and Methods for details). From commercially available side chain alternatives, we identified five potential candidates for R replacements: 1H-imidazole-5-pentanoic acid, 1H-imidazole-1-pentanoic acid, 7-aminoheptanoic acid, D-arginine and L-citrulline (Supplementary Figure   1) . We next synthesised 3BP2 TBM octapeptides, incorporating the five arginine substituents at position 1, followed by fluorescence polarization (FP) assays to assess competition of the peptides with a Cy5-labelled TBM peptide probe (Supplementary Figure   1 ). We used a 16-mer TBM peptide (LPHLQRSPPDGQSFRSW, W introduced to measure A280) derived from the model substrate 3BP2, a signaling adapter protein 4 , as a positive control for a competitor, and a corresponding non-binding TBM peptide bearing a glycineto-arginine substitution at position 6 4 as a negative control. Whilst we observed no binding for the G6R negative control, we measured an IC50 of 22 μM for the 3BP2 16-mer peptide (Supplementary Figure 1) . The 8-mer RSPPDGQS TBM peptide displayed an IC50 of 34 μM.
Substituting L-arginine for D-arginine caused a five-fold drop in potency to 175 μM, highlighting the importance of side chain geometry. Both imidazole moiety peptides displayed IC50 values in the 500 μM range. The 7-aminoheptanoic acid and citrulline peptides showed poor competition and precipitation at high concentrations (Supplementary Figure 1) . In conclusion, these observations demonstrated that the essential arginine residue of the TBM cannot be easily substituted.
Primary fragment screens
Given the anticipated challenges associated with replacing the TBM arginine residue, we pursued a fragment screening strategy to sample a wide range of chemical space, with the aim of finding novel, ligand-efficient small molecules that target tankyrase ARCs and to identify alternative binding 'hotspots' away from the "arginine cradle" of the TBM binding site. We screened The Institute of Cancer Research (ICR) fragment library 53 in parallel against TNKS2 ARC5 using differential scanning fluorimetry (DSF), and TNKS2 ARC4 using ligand-observed nuclear magnetic resonance (NMR) spectroscopy techniques. We used the 3BP2 TBM peptide and its non-binding mutant variant as positive and negative controls, respectively.
Primary fragment screening by DSF
Our pilot studies showed that among all TNKS2 single ARCs that we could produce recombinantly (ARCs 1, 4 and 5) 49 , ARC5 displayed the lowest melting temperature (Tm) and the largest shift in melting temperature upon addition of the 3BP2 TBM peptide (DTm) (Figure 2A ). Therefore, we chose TNKS2 ARC5 for screening by DSF, anticipating the largest signal window for measuring changes in Tm upon fragment binding. DMSO concentrations up to 10% of total sample volume had a negligible effect on TNKS2 ARC5
Tm (Supplementary Figure 2A) . We explored the stabilization of TNKS2 ARC5 by the abovementioned TBM peptide derivatives and found a good correlation between the DSF data and the FP data obtained with TNKS2 ARC4, further demonstrating the suitability of the DSF assay (Supplementary Figure 2B) .
We screened 1869 compounds in duplicate at a concentration of 500 µM, which we considered a reasonable compromise between having a sufficiently high concentration to identify weak binders while minimizing the likelihood of false positives through fragment precipitation and aggregation, and non-specific binding. K for compounds that destabilised the ARC ( Figure 2B ).
We assessed the robustness of the assay for screening. The standard deviation for both the DMSO-only (Tm, 0) and 3BP2 peptide positive control (Tm, peptide) melting temperatures across all plates was approximately 1 K, indicating that any shifts below 1 K may be attributable to noise. We calculated the Z factor (Z') using the mean melting temperature and s for the whole fragment library, with the DMSO-only samples as the baseline and 3BP2 TBM peptide samples as positive controls. A value of Z' = 0.9 was obtained, indicating that the assay was robust.
We prioritised hits that stabilised TNKS2 ARC5 if they had a change in melting temperature of greater than 1.8 K in at least one replicate (both DTm(IP) and DTm(1st derivative) methods of analysis), and de-prioritised those that showed a significant discrepancy between DTm(IP)
and DTm(1st derivative) values, indicating an unusual melting curve shape. Negative shift hits that destabilized the protein were only taken forward if they were significant in both replicates, and with both methods of DTm analysis. (The higher stringency was applied as molecules that destabilize the protein can be harder to advance and develop into lead-like compounds 54, 55 .) We thus progressed 56 hits into validation assays. Of these, 48 conferred a positive thermal shift and stabilized TNKS2 ARC5; 8 had a negative thermal shift and destabilized the protein. We next assessed compound purity and structural integrity of hits from the DSF screen by liquid-chromatography-mass-spectrometry (LC-MS) and measured their solubility by NMR. Five compounds failed the LC-MS quality control, and eight were of insufficient solubility by NMR (<100 µM in aqueous buffer with 5% DMSO). Two compounds didn't contain any aromatic protons (required for our NMR solubility assay), and an additional two were no longer commercially available for re-purchase. A total of 17 of compounds were therefore excluded from further analysis. An in-silico pan assay interference compounds (PAINS) screen was applied to the hit fragments to highlight any possible issues in carrying the hits forward 56 . No compounds were flagged as problematic in the PAINS screen.
Fragment binding validation for DSF hits
39 hits from the DSF screen were suitable for follow-up by ligand-observed NMR methods.
We re-purchased fragments and performed T2 relaxation-edited (CPMG-edited) and waterLOGSY experiments for each fragment with TNKS2 ARC5. We explored saturation transfer difference (STD) NMR, also using TNKS2 ARC5, but the assay was not sensitive enough to produce a reliable binding signal, likely due to the relatively small size of a single ARC protein (data not shown). High ligand concentrations were required to achieve sufficient signal, which in turn could lead to false-positive hits due to non-specific binding.
Using the relaxation-edited assay, we tested each fragment in three independent measurements ( Figure 2C ), unless we obtained two negative results (non-binding) in the first two experiments. We next used waterLOGSY to further evaluate compounds that showed a substantial decrease (>15% reduction in peak integrals) upon protein addition in at least one out of three relaxation-edited experiments. We classified fragments with a negative NOE signal in waterLOGSY as binders ( Figure 2D ). As a negative NOE for the compound-only sample could indicate aggregation, we flagged these compounds as potentially problematic. We identified 14 fragments that bound to TNKS2 ARC5 by both relaxation-edited and waterLOGSY methods (0.78% hit rate). We next tested whether binding of these fragments occurred competitively with the 3BP2 TBM peptide, and also if they bound to TNKS2 ARC4, as competition with peptide binders at various different ARCs will be a prerequisite for an efficient substrate binding antagonist. Three fragments (1, 2, 3)
bound to both TNKS2 ARC4 and ARC5 and were competitive with the TBM peptide (0.16% hit rate) ( Figure 2E ). Three further fragments also bound to both ARCs, but were not TBM competitive by NMR.
Primary fragment screening by NMR
The hit rate for compounds confirmed to bind as evaluated by NMR was relatively low, at 0.78%, and only 0.16% for fragments competitive with a TBM peptide. Different screening assays often give distinct hit fragments 57 . There is no consensus on the most appropriate assays to use for fragment screening, especially against challenging targets such as proteinprotein interactions. Often several orthogonal methods are used in series to narrow down fragment hits, or a combination of biophysical and biochemical assays to exclude false positives and identify binders that modulate protein activity 53 . We therefore carried out an additional primary screen using T2 relaxation-edited ligand-observed NMR on TNKS2
ARC4, using a subset of the ICR fragment library that was compatible with NMR. We screened 1100 compounds in pools of four structurally dissimilar molecules with nonoverlapping proton resonances ( Figure 3A , B) 58 . We split the top 100 hits into two groups for individual re-testing: those with a signal change ≥39% (3s, 35 compounds), and those with a signal change of 26 -39% reduction (2 -3s, 65 compounds) ( Figure 3A ). We tested fragments of the first hit group (>3s) individually using the T2 relaxation-edited NMR assay.
We tested those of the second hit group (2 -3s) in a waterLOGSY NMR experiment, reasoning that this may rescue any genuine binders with a relatively small signal in the relaxation-edited assay. Nine out of 35 compounds from hit set 1 displayed a significant intensity change (≥26% reduction) upon protein addition when tested individually. We confirmed seven out of 65 compounds from hit set 2 to bind in the waterLOGSY assay. We tested these 16 compounds in further T2 relaxation-edited and waterLOGSY experiments, and in competition with the 3BP2 TBM peptide. Of the 16 compounds, two (4 and 5) were competitive with the TBM peptide by relaxation-edited NMR; one compound (5) also showed peptide competition by waterLOGSY ( Figure 3C ).
In addition to the hits identified uniquely by either the DSF or NMR, the two orthogonal screens also shared two common hits (compounds 6 and 7, Figure 3D ). Retrospective analysis of the DSF screening data revealed that compound 5 was excluded during the DSF analysis due to poorly shaped, biphasic melt curves. This resulted in large discrepancies
between DTm values calculated by the inflection point (1.6 K) and 1 st derivative methods (8.1 K) when the second peak was used to calculate Tm. We also discounted other compounds for poor melt curve shape; however, none of these were identified in the orthogonal NMRbased screen.
Fragment hit validation and Kd determination
We next tested validated hits from both the DSF and NMR screens (17 compounds 
Fragment analog SAR
We next sought close structural analogs of hit fragments 3 and 5 to gain early insights into structure-activity relationships (SAR) and binding modes of hit fragments. We initially tested the analogs using both relaxation-edited and waterLOGSY NMR assays against TNKS2 ARC4 (Table 1) to the furan ring (21) or substituting the para-fluorine for a meta-chlorine (22) were also not tolerated.
Compound 9 (Table 1, Figure 4A ) combined features of both fragments 3 and 5, namely the quinoxaline group of fragment 5, the amide linker shared by both fragments and the furan group of fragment 3. We observed that in the relaxation-edited NMR experiments, peaks corresponding to the quinoxaline displayed a larger reduction upon ARC addition than peaks attributed to furan ( Figure 4A ). This suggested that the quinoxaline moiety more substantially contributes to the binding, and several analogues of the quinoxaline hit were confirmed to bind to TNKS2 ARC4.
Fragment binding affinity
The increased solubility of compound 9 compared to compound 5 allowed complete saturation in a protein-observed NMR titration experiment against TNKS2 ARC4, yielding an apparent Kd of 1050 µM ( Figure 4B , C). We next used isothermal titration calorimetry (ITC) to confirm the compound 9:TNKS2 ARC4 binding affinity, titrating the fragment (5 mM,
1% DMSO) into TNKS2 ARC4 (200 µM, 1% DMSO). A global analysis of 5 experiments
confirmed the affinity to be in the region of 1 mM (1200 ± 380 µM) ( Figure 4D , Table 2 ).
Fragments bind to multiple TNKS and TNKS2 ARCs
The anticipated functional redundancy between ARCs and the existence of two tankyrase paralogs will require efficient substrate binding antagonists to ideally bind all TBM-binding ARCs of both TNKS and TNKS2. The high conservation of the peptide-binding pocket suggests that this goal should be achievable 4 . We tested binding of compound 9 to all TNKS and TNKS2 ARCs using the relaxation-edited NMR assay ( Figure 4E , Table 3 an extended hydrophobic pocket adjacent to the glycine sandwich, which may participate in fragment binding. Whilst the low affinity of the current fragments may sensitize them to small differences between the TBM-binding ARCs, further developed molecules will need to be engineered to be resistant to such variability.
In-silico modeling of fragment hotspots
We next sought to determine the fragment binding site on the ARC. To gain insights into plausible fragment binding sites and identify potential hotspots, we undertook an in-silico fragment binding experiment by computational solvent mapping using the FTMap program 59, 60 . FTMap identifies pockets where several different small organic molecule probes bind and cluster together; these consensus sites represent potential hotspots for fragment binding. We docked a set of 16 probe molecules into the crystal structure TNKS2 ARC4, from the ARC4:3BP2 TBM co-crystal structure 4 . FTMap identified ten areas of probe clustering, eight of which overlapped with the known peptide-binding groove ( Figure 5A ).
The lowest-energy consensus site, and hence most ligandable pocket identified, was the primarily hydrophobic "central patch" adjacent to the "glycine sandwich". The second most ligandable site predicted was the "arginine cradle". These predicted hotspots coincide with the experimentally determined hotspots for TBM peptide binding, based on structural data, site-directed mutagenesis and an amino acid scan of the 3BP2 TBM 4, 61 . One hotspot was detected in an extension to the "central patch", suggesting that it may be possible to grow fragments in a way that utilises this extended pocket. Of note, this "central patch extension" is occupied by a glycerol molecule in the TNKS2 apo-ARC4 crystal structure 
Ligand-observed NMR with mutant TNKS2 ARC4 proteins
We used three previously designed TNKS2 ARC4 mutant variants 4 to explore potential binding determinants for fragment 9. A WFE591/593/598AAA triple-mutation abrogates three key residues in the "arginine cradle"; YY536/569AA truncates two tyrosine residues that form the "glycine sandwich", and L560W introduces a bulky residue into the "central patch" that sterically clashes with the TBM peptide (see Figures 5A, B for location of the mutated residues). We tested binding of compound 9 to the wild-type and mutant ARCs by ligand-observed NMR, using the relaxation-edited assay ( Figure 5C , Table 4 ). While mutation of the "arginine cradle" had no effect on fragment binding, mutation of the aromatic residues sandwiching the TBM glycine (YY536/569AA) fully abrogated binding in the relaxation-edited NMR assay. Binding was impaired but not abolished for the "central patch" mutant variant (L560W). We confirmed these results in the orthogonal waterLOGSY assay ( Figure 5D , Table 4 ).
Fragment binding site mapping by protein-observed NMR
To directly identify the compound 9 binding site on the ARC, we analysed the titrations of compound 9 with 15 N-labeled TNKS2 ARC4. The higher solubility of fragment 9, compared to that of compounds 3 and 5, meant that much larger CSPs could be achieved (Supplementary Figure 4C) . At an ARC4:compound ratio of 1:16, close to signal saturation (see Figure 4C ), we observed substantial CSPs for the following main-chain resonances:
with CSPs above 2 s from the mean CSP for S527, T528, F532, Y536, N565 and A566, and with CSPs within 1-2s for A499, K501, D521, I522, L530, A534, G535 and L563 ( Figure 6 ).
All CSPs occurred in the fast-exchange regime and included those observed for compounds 3 and 5 ( Figure 6 , Supplementary Figure 4C ). Mapping the CSPs onto the crystal structure of TNKS2 ARC4 bound to the TBM peptide from 3BP2 4 revealed the substantial overlap of the fragment and TBM peptide binding site in the "aromatic glycine sandwich", the "central patch" and residues in the close vicinity to these areas, in agreement with the mutagenesis studies ( Figure 6A ). In conclusion, compound 9 occupies the most ligandable pocket on the ARC and a major binding hotspot of TBM peptides.
Conclusions and Discussion
Here we identify a quinoxaline-based set of fragments that bind to the substrate/proteinbinding ARCs of tankyrase at the same site as TBM peptides. We show that the fragments bind in the "aromatic glycine sandwich" and "central patch" regions, major known hotspots of TBM binding. These fragments, even at their current affinities in the millimolar range, 
"aromatic glycine sandwich" (blue), and (4) "C-terminal contacts" (cyan). TBM octapeptide amino acid positions are numbered. 
Materials and Methods
Fragment screening using a thermal shift assay
For the screen, a C1000 thermal cycler (Bio-Rad) was used to record melt curves. SYPRO
Orange was purchased as a 5000 ´ stock in DMSO from Sigma Aldrich. The ICR fragment library was available as 100 mM stocks in DMSO, and dispensed (25 nL) using an ECHO acoustic liquid handling system into white 384-well PCR plates (Framestar, 4titude). Wells were backfilled with DMSO (225 nL). Buffer (25 mM HEPES-NaOH pH 7.5, 100 mM NaCl, 2 mM TCEP, 2.75 µL) was added, followed by TNKS2 ARC5 (1 µL, 100 µM stock) and then SYPRO orange dye (1 µL, 25´). The plate was centrifuged after the addition of each reagent Compounds were tested in duplicate, and hits were defined as fragments that gave a DTm outwith 2 s from the mean in one or both replicates.
For the experiment shown in Figure 2A , ARC and 3BP2 TBM peptide concentrations were 20 and 200 µM, respectively, in 50 mM HEPES-NaOH pH 7.5, 100 mM NaCl, 2 mM TCEP and a total volume of 25 µL. Sypro Orange was added at 5´. Data were recorded from 4-95 °C, with the temperature ramped by 0.5 °C every 15 s, using a CFX384 thermal cycler (BioRad). Data were analysed by non-linear regression in GraphPad Prism using a Bolzmann sigmoid with linear baselines. DTm values were determined using the inflection point method.
NMR experiments
A Bruker 500 MHz instrument, fitted with a 1.7 mm TXI microprobe was used for all ligandobserved and protein-observed NMR experiments, with 1.7 mm SampleJET NMR tubes (Bruker).
Fragment solubility assay
Fragments were dispensed into a 384-well plate (250 nL of 100 mM stock in DMSO, 500 µM final concentration) using an ECHO acoustic dispenser. DMSO (2.25 µL) was added, then NMR buffer (47.5 µL, 25 mM HEPES-NaOH pH 7.5, 100 mM NaCl, 1 mM TCEP, 10% D2O). The plate was centrifuged (1 min, 1000 x g) before the solutions were transferred to 1.7 mm NMR tubes using a Gilson liquid handling system.
1
H NMR spectra were recorded with the DMSO and water signals dampened. 100 µM caffeine was used as an external standard to quantify the ligand signals.
T2 relaxation-edited NMR assay
Fragments were dispensed in duplicate into a 384-well plate (250 nL, 100 mM stock in DMSO). Wells were backfilled with DMSO (2.25 µL). Tankyrase ARC protein (47.5 µL, 20 µM in 25 mM HEPES, pH 7.5, 100 mM NaCl, 2 mM TCEP, 10% D2O) was added to the 'protein' samples; buffer only (47.5 µL) was added to the 'compound-only' samples.
Solutions were transferred to 1.7 mm NMR tubes using a Gilson liquid handler.
H NMR
spectra were recorded, with the DMSO and water signals dampened. A relaxation spin filter was applied at 400 ms 64 . Data were processed using Bruker Topspin 3.14. Lines were broadened with LB = 3.0, and the baseline was corrected between 6.0 -10.0 ppm. The average integral for all peaks between 6.0 -10.0 ppm was calculated, and the difference between compound-only and compound-plus-protein samples was compared. A reduction in signal integrals of ≥15% was classified as a hit. For competitive experiments, 3BP2 (100 µM) was added, and the spectra recorded and processed as above. The variability in signal reduction in the relaxation-edited experiment was previously determined as approximately ±10% (Liu et al., unpublished observations), so replicates were run to account for this variability, to ensure that compounds that had a weak reduction in signal that did not meet the arbitrary cut off were not erroneously excluded.
WaterLOGSY NMR assay
Fragments were dispensed in duplicate into a 384-well plate (250 nL, 100 mM stock in DMSO). Wells were backfilled with DMSO (2.25 µL). Tankyrase ARC protein (47.5 µL, 20 µM in 25mM HEPES-NaOH pH7.5, 100 mM NaCl, 2 mM TCEP, 10% D2O) was added to the samples containing protein; buffer only (47.5 µL) was added to the compound-only samples. Solutions were transferred to 1.7 mm NMR tubes using a Gilson liquid handler.
1 H NMR spectra were recorded, with the DMSO signal dampened. The bulk water signal at 4.7 ppm was selectively inverted. Data were processed using Bruker Topspin 3.14 65 .
Fragment screening using a T2 relaxation-edited ligand-observed NMR assay
Cocktails of four structurally distinct compounds were created using MNova Screen software to ensure there was no significant overlap of peaks in the region of interest (5.5 -9.5 ppm).
Fragments were screened at 1 mM each, with 4% v/v DMSO. Compounds were dispensed in duplicate using an ECHO acoustic dispenser (0.5 µL of each, 100 mM stock in DMSO).
TNKS2 ARC4 (35 µM in 25 mM HEPES-NaOH pH 7.5, 100 mM NaCl, 2 mM TCEP, 10% D2O) was added to one cocktail, and buffer alone to the other replicate for a control sample of compounds alone. Mixtures were incubated for 20 min at room temperature, and then transferred into 1.7 mm NMR tubes.
1
H relaxation-edited NMR spectra were collected with double solvent suppression applied to dampen the water and DMSO solvent signals.
1 H spectra of each individual compound were used as reference spectra.
Data were processed using Bruker Topsin 3.14, then analysed using MNova Screen software. Only peaks between 5.5 and 9.5 ppm were considered. Peaks with a height of <5% maximum peak height within the region of interest were considered to be noise, and the minimum matched peak level was set at >51%. The relative peak intensity change (I) was calculated by equation 1 for all peaks in the 5.5 -9.5 ppm region, for each compound. 
Mass spectrometry
Fragment quality control
An Agilent 6520 Quadrupole time of flight (qToF) mass spectrometer, with a 1200 series HPLC, fitted with an ESI/APCI multimode ionisation source was used. All solvents were modified with 0.1% formic acid. Fragments (2 mM in DMSO) were injected (2 µL) onto a
Purospher STAR RP-18 end-capped column (3 µm, 30 x 4 mm, Merck KGaA).
Chromatographic separation was carried out over a 4-min gradient elution (90:10 to 10:90 water:methanol) at 30 °C. UV-Vis spectra were measured at 254 nm on a 1200 series diode array detector (Agilent). The eluent flow was split, with 10% infused into the mass spectrometer. Eluent and nebulising gas were introduced perpendicular to the capillary axis, and applying 2 kV to the charging electrode generated a charged aerosol. 
Protein expression and purification
Tankyrase ARC constructs were produced as previously described (see Pollock et al, 2017 for construct details) 49 . Uniformly (45 µL, 25 mM HEPES-NaOH pH 7.5, 100 mM NaCl, 1 mM TCEP, 10% D2O) was used as the baseline sample. Peptide titration samples were prepared by diluting peptide (table 5) with NMR buffer (45 µL), then adding TNKS2 ARC4 (300 µM final concentration; 5 µL of 3 mM stock). Separate samples were prepared for each concentration point.
Fragments titration samples were prepared by diluting fragments in NMR buffer (25 mM HEPES-NaOH pH7.5, 100 mM NaCl, 1 mM TCEP, 10% D2O) and backfilling with DMSO to keep a constant DMSO concentration of 5% (table 6) . The pH of the peptide and fragment stocks (at 3 mM) was confirmed to exclude the possibility that peak shifts were due to changes in pH during the titration.
Analysis of protein-observed NMR data
Data were processed in Bruker Topspin 3.14 and analysed using CcpNmr Analysis software 
Kd values were calculated for each peak that shifted individually. The mean of all shifting peaks was then calculated to give an apparent Kd value 67 .
Kd determination using isothermal titration calorimetry
An ITC200 (MicroCal) instrument was used, fitted with a twisted syringe needle, stirring at 750 rpm. All solutions were degassed using a ThermoVac before use. The reference cell was filled with buffer (200 µL, 25 mM HEPES-NaOH pH 7.5, 100 mM NaCl, 1 mM TCEP, 1% v/v DMSO). The cell was filled with TNKS2 ARC4 (488-649) (200 µL, 200 µM in identical buffer as above). 20 injections (1 x 0.5 µL, then 19 x 2 µL) of compound 9 (5 mM, 1% v/v DMSO in buffer) were performed, with 180 s between injections. Blank correction was performed by titrating compound into buffer alone (25 mM HEPES-NaOH pH 7.5, 100 mM NaCl, 1 mM TCEP, 1% v/v DMSO) using the same injection protocol as above. The first injections from each run were discarded from data analysis. Data were analyzed using Origin software with a one-site binding model. Titrations were repeated n=5. Global analysis was performed using SEDPHAT software 68 .
In-silico prediction of fragment hotspots and pockets on TNKS2 ARC4
For the FTMap analysis, TNKS2 ARC4 chain D from the TNKS2 ARC4-3BP2 co-crystal structure (PDB 3TWR) 4 was submitted to the FTMap web server (ftmap.bu.edu) and analyzed under protein-protein interaction mode, as detailed under the published conditions 59, 60 .
For pocket identification using the Roll algorithm, TNKS2 ARC4 chain D from the TNKS2 ARC4-3BP2 co-crystal structure was submitted to the Pocasa 1.1 web server (altair.sci.hokudai.ac.jp/g6/service/pocasa/) and analyzed with the following parameters:
probe radius, 2 Å; single point flag, 16; protein depth flag, 18; grid size, 1 Å; atom type, protein.
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